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https://doi.org/10.1016/j.cels.2020.05.012SUMMARYThe COVID-19 pandemic is an unprecedented global challenge, and point-of-care diagnostic classifiers are
urgently required. Here, we present a platform for ultra-high-throughput serum and plasma proteomics that
builds on ISO13485 standardization to facilitate simple implementation in regulated clinical laboratories. Our
low-cost workflow handles up to 180 samples per day, enables high precision quantification, and reduces
batch effects for large-scale and longitudinal studies. We use our platform on samples collected from a
cohort of early hospitalized cases of the SARS-CoV-2 pandemic and identify 27 potential biomarkers that
are differentially expressed depending on the WHO severity grade of COVID-19. They include complement
factors, the coagulation system, inflammation modulators, and pro-inflammatory factors upstream and
downstream of interleukin 6. All protocols and software for implementing our approach are freely available.
In total, this work supports the development of routine proteomic assays to aid clinical decision making and
generate hypotheses about potential COVID-19 therapeutic targets.INTRODUCTION
The ongoing SARS-CoV-2 pandemic has highlighted the press-
ing need for technologies that can accelerate our understanding
of emerging diseases in order to (1) find markers that define dis-
ease severity, have prognostic value, or define a specific phase
of the disease; (2) identify preventive strategies; and (3) discover
therapeutic targets. PCR-based diagnostics can be imple-
mented and scaled quickly but do not provide information about
severity of the disease as well as likely illness trajectories (Chen
et al., 2020; Corman et al., 2020). Furthermore, conventionalCell Systems 11, 11–24
This is an open access article undbiomarker as well as serological assays depend on affinity re-
agents, such as antibodies. Developing these takes time and re-
quires prior knowledge of epitopes and the disease mechanisms
(Petherick, 2020). Indeed, the host response to each viral infec-
tion is significantly different, specifically, as several viruses can
evade the host immune system (Bussey and Brinkmann, 2018;
Kikkert, 2020). Each novel infective agent requires a new assess-
ment of the host response, aswell as requires a unique set of bio-
markers for predicting disease trajectories.
Mass spectrometry (MS)-based proteomics does not depend
on affinity reagents and can be set up in an untargeted fashion,, July 22, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 11
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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It can quickly deliver substantial amounts of clinical and biolog-
ical information from accessible biological material, such as
blood plasma or serum. MS-based proteomics hence has the
potential to become an ideal technology to be applied
in situations when rapid responses are required. Currently,
MS-based proteomic workflows are well established in research
laboratories, where they are routinely used for biomarker discov-
ery and profiling (Bruderer et al., 2019; Geyer et al., 2016a,
2016b, 2017, 2019; Liu et al., 2015; Niu et al., 2019; Wewer Al-
brechtsen et al., 2018).
Increasingly, MS-based proteomics is also entering regulated
clinical and diagnostic environments (He, 2019; Mischak et al.,
2012; Crutchfield et al., 2016). It has the potential to yield com-
plex and predictive biomarker signatures that support clinical
decision making, as well as to enable the prediction of patient
trajectories via machine learning methods with datasets of suffi-
cient depth and size (Ahadi et al., 2020). However, in clinical
practice, its potential is yet to be completely realized. For routine
applications, MS-based proteomic methods must combine pre-
cision, reproducibility, and robustness with low cost and high
throughput, such that results can be routinely compared within
and between clinical studies and laboratories (Geyer et al.,
2017, 2019; Nilsson et al., 2010; Wright and Van Eyk, 2017).
These requirementsmight necessitate a compromise with prote-
omic depth, which has often been a key objective of proteomics
in research settings, but which has been, in turn, often achieved
through long measurement times and high cost (Bruderer et al.,
2019; Geyer et al., 2016a; Liu et al., 2015). A further hurdle is that
current MS-based proteomic workflows require, partially due to
their dependency on chromatographic flow rates in the range of
nanoliters or low microliters per minute, a high level of expert
knowledge to achieve the level of necessary robustness for im-
plementation in the clinical laboratory.
Here, we present a redesigned high-throughput MS platform
that enables the cost-effective (less than 10V for consumables
per sample) in-depth analysis of disease susceptibility and pro-
gression in patients as well as biomarker discovery. Our platform
is optimized at all steps from sample preparation, chromatog-
raphy, and data acquisition to data processing, in comparison
to existing research pipelines (Bache et al., 2018; Bekker-Jensen
et al., 2020; Bian et al., 2020; Bluemlein and Ralser, 2011; Bru-
derer et al., 2019; Geyer et al., 2016a; Liu et al., 2015; M€uller
et al., 2020; Vowinckel et al., 2018). It includes a semi-automated
sample preparation workflow that scales to high sample
numbers through the use of liquid handling robotics and mini-
mum hands-on-time and includes effective strategies tomitigate
longitudinal batch effects. It also makes use of short-gradient
high-flow liquid chromatography (LC), a technology that is the
basis of several FDA-approved clinical assays (Grebe and Singh,
2011; Nair and Clarke, 2016), applicable to high-throughput pro-
teomic experiments. Using this approach, we were able to
reduce measurements to 5-min gradient length, inter-runtime
to 3 min or less, as well as to use flow rates of 800 mL/min,
thereby substantially increasing sample turnover and reducing
costs, while increasing stability and precision.
We first benchmarked the platform on a cohort-based epide-
miological study, Generation Scotland (GS) (Smith et al., 2013),
and at considerably higher throughput, demonstrated a level of12 Cell Systems 11, 11–24, July 22, 2020precision and consistency that, to our knowledge, is yet un-
achieved in comparable large-scale proteomic studies. We
then employed this workflow in an immediate response to the
SARS-CoV-2 pandemic outbreak in Germany, by applying it to
a cohort that includes the first COVID-19 patients hospitalized
at the Charité Universit€atsmedizin Berlin. We measured samples
from a primary exploratory cohort comprising thirty-one COVID-
19 patients to identify clinical classifiers, candidate biomarkers
as well as potential targets that picture the host immune
response specific to a SARS-CoV-2 infection (Figure 4A). We
validated these on a smaller cohort of seventeen independent
patients and fifteen healthy volunteers (Table S1). We identified
protein expression signatures that can classify COVID-19 pa-
tients according to WHO grading, introduced as of April 2020
(World Health Organization, 2020).
Our analysis associates several proteins with COVID-19
severity that have not been previously associated with the infec-
tion and the host response. These are alpha-1B-glycoprotein
(A1BG), beta and gamma-1 actin (ACTB;ACTG1), monocyte dif-
ferentiation antigen and lipopolysaccharide co-receptor CD14,
lipopolysaccharide-binding protein (LBP), galectin 3-binding
protein (LGALS3BP), leucine-rich alpha-2-glycoprotein (LRG1),
haptoglobin (HP), protein Z-dependent protease inhibitor (SER-
PINA10), apolipoprotein C1 (APOC1), gelsolin (GSN), and trans-
ferrin (TF). Our results highlight the role of complement factors,
the coagulation system, several inflammation modulators as
well as pro-inflammatory signaling both upstream and down-
stream of interleukin (IL)-6. In addition, our study provided evi-
dence that proteomic signatures have the potential to outper-
form conventional clinical assays. Two individuals with differing
proteomic signatures were identified through a clustering
approach. In one case, a clinical re-assessment changed the
diagnosis (the patient was in fact suffering from an influenza
type B infection) and revealed in the other case a strong comor-
bidity caused by anti-cancer chemotherapy. None of the
currently applied clinical tests spotted this situation.
In total, our study demonstrates the value and power of robust
high-throughput MS in a global public health crisis. Very fast and
reliable proteome technologies can play a vital role both in clin-
ical classification as well as in the rapid identification of thera-
peutic targets against arising infecting agents.
RESULTS AND DISCUSSION
A Platform for Clinical Proteomics Yields High
Quantitative Precision at Low Costs and High
Throughput
We addressed throughput, precision, costs, and practical hur-
dles in clinical implementation of MS-based proteomics, by
designing a proteomics platform, in which we refined sample
preparation, chromatography, mass spectrometric acquisition,
and data analysis. Our workflow reaches a high level of stan-
dardization and documentation, for which ISO 13485 was used
as a reference (Figure S1). After the transfer of the clinical plasma
or serum samples, obtained with standard operating proced-
ures, to 96-well plates, all pipetting and mixing steps are con-
ducted with liquid handling robots. The workflow has a total
hands-on time of around 3.5 h and is designed so that a single
person using a single liquid handling unit can start and complete
ll
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plates containing up to 768 proteome samples exit the workflow
every day and are ready for the mass spectrometric analysis.
Among several improvements in handling (see STARMethods
for details), the preparation workflow includes a simple but effec-
tive handling improvement that mitigates batch variation in sam-
ple preparation reagents, which has proven so far a major and
prohibitive contributor to quantification inconsistencies in
(large-scale) proteomic experiments (Fu et al., 2018; Lowenthal
et al., 2014; Piehowski et al., 2013). Instead of pipetting reagents
on the samples at each step, initial common stock solutions
(urea and ammonium bicarbonate buffer, dithiothreitol, iodoace-
tamide, formic acid, and trypsin) are pre-filled into multi-well
plates and are then stored at 80C for whole projects in perpe-
tuity. These plates enter the workflow at different stages (Fig-
ure 1), thereby not only reducing hands-on time but maintaining
the exact same reagents for projects of, in theory, unlimited
scale. A second key step concerns the cleanup of the digested
peptides, which is done with 96-well solid-phase extraction
plates (Bennike et al., 2018; Bruderer et al., 2019). In our work-
flow, four are processed in parallel to reduce technical variability.
Finally, the inclusion of sample preparation controls on each
plate enables cross-batch normalization, to correct batch effects
in case these emerge at the sample preparation or the acquisi-
tion step of the workflow (Figure 1).
Next, we developed a data acquisition scheme that could be
implemented in regulated environments without major hurdles
and maintains very low variability across large sample series.
Here, we focused on the implementation of a high-flow chro-
matographic regime in a proteomic workflow. The current stan-
dard technique for bottom-up proteomics, nano-flow LC, used
owing to its high sensitivity, is a main contributor to batch vari-
ability in LC-MS experiments (Gama et al., 2013; Shishkova
et al., 2016). Several recent studies have shown that run-to-run
variability improves by switching from nano-flow to micro-flow
regimes or to specialized chromatographic devices that operate
with pre-formed gradients. These allow faster runtimes and sam-
ple turnover, show better retention time stability, and improve
column lifetime (Bache et al., 2018; Bian et al., 2020; Bruderer
et al., 2019; Vowinckel et al., 2018).
Alternatively, high-flow LC (also known as analytical LC) in
conjunction with very fast chromatographic gradients, a technol-
ogy that reaches the requirements of regulated clinical labora-
tories, could further and substantially improve throughput and
chromatographic properties. However, typically it has not been
applied to short-gradient proteomics for two important reasons.
First, on this type of fast chromatography, conventional mass
spectrometric acquisition schemes do not reach sufficient sam-
pling velocity in data-dependent mode (as peaks elute too fast).
Second, when using data-independent acquisition (DIA)
schemes, which do not sample each peak individually, conven-
tional software cannot deconvolute the interference-rich short-
gradient data produced (Demichev et al., 2020; Messner
et al., 2019).
We overcame these issues and developed an acquisition
scheme based on 5-min water to acetonitrile chromatographic
gradients at a flow rate of 800 mL/min. Separating tryptic digests
of non-depleted human plasma using an 1290 Infinity II UPLC
(Agilent) or H Class UPLC systems (Waters) coupled to a Triple-TOF 6600 (Sciex) mass spectrometer illustrates that total ion
chromatograms (TICs) are virtually unchanged over repeated
injections (Figure 2A). The nearly complete overlap of the TICs in-
dicates not only the stability of the applied chromatographic sys-
tem but also the stability of the electrospray, which is facilitated
by the gases that assist the desolvation process in high-flow ion
sources. By using a short 5-cm column and by increasing the
flow rate post-gradient to 1,200 mL/min and 1,000 mL/min during
washing and equilibration, respectively, we were able to reduce
the total runtime, including overhead, to less than 8 min. In this
particular test, the setup allows a theoretical throughput of 180
samples/day on a single mass spectrometer, an at least 5-fold
improvement compared with microLC or nanoLC platforms opti-
mized for throughput (Bruderer et al., 2019; Geyer et al., 2016a;
Vowinckel et al., 2018). Moreover, the columns used in high-flow
chromatography have higher capacities and thus are less prone
to carryover. Indeed, blank injection after 10 acquisitions of non-
depleted plasma tryptic digests shows no significant carryover
even with an applied wash time of less than 1 min (Figure 2A).
The separation of a K562 cell line tryptic digest (Promega) at
different gradient lengths illustrates the chromatographic prop-
erties achieved. The high-flow setup achieved a median peak
full width at half maximum (FWHM) of 3 s with a 20-min gradient
length. For comparison, an extensively optimized micro-flow LC
(Demichev et al., 2020; Messner et al., 2019), achieved a FWHM
of 5 s, at the same gradient length (Figure 2C). Furthermore, high-
flow gradients as fast as 5 min resulted in peak capacities com-
parable to the highly optimized 20-min micro-flow setup (Demi-
chev et al., 2020; Messner et al., 2019) (Figure 2D). In order to
achieve a sufficiently fast mass spectrometric duty cycle, we
used a q-TOF instrument with a very fast sampling rate (Schilling
et al., 2017) and applied SWATH-MS, a DIA method specifically
developed to minimize stochastic elements in data acquisition
(Gillet et al., 2012; Ludwig et al., 2018). To record sufficient
data points per chromatographic peak, we optimized the
method for duty cycles of 700 ms and scan a precursor mass
range of m/z 450–850 using 25 windows with variable window
size (Table S6) and with 25-ms accumulation time.
In order to deconvolute the complex data recorded, we built
on our recent developments of DIA-NN software, that includes
several algorithms that boost the number of true positive precur-
sor identifications in the short-gradient DIA-MS runs. DIA-NN
can handle complex short-gradient data as it contains algo-
rithms that correct for signal interferences and uses deep neural
networks to assign confidence scores to peptide-spectrum
matches and identify true positive signals (Demichev et al.,
2020). Applied to analyzing 5 mg of human cell line (K562) tryptic
digest, the short-gradient high-flow method yielded 2,829
unique proteins (at 1% FDR) in triplicate injections, while the
numbers of unique proteins quantified with a coefficient of vari-
ation (CV) less than 20% and less than 10% were 1,873 and
1,349, respectively (Figure S2E). Hence, despite the ultra-high
throughput and the use of high-flow chromatography, the analyt-
ical method is able to achieve proteomic depth even on complex
samples. Finally, we improved the DIA-NN (version 1.7.10) work-
flow for the high-throughput processing of plasma and serum
proteomes, through integration of the MaxLFQ protein quantifi-
cation algorithm (Cox et al., 2014) in a DIA-NN R-package. Orig-
inally, MaxLFQ was designed for shotgun-MS studies but wasCell Systems 11, 11–24, July 22, 2020 13
A
B
Figure 1. A High-Throughput Proteomics Platform for Large-Scale and Longitudinal Clinical Proteomic Studies
(A) Experimental part of the workflow. Receipt and storage (green boxes): clinical or epidemiological samples are collected using a standard operating procedure,
received, and stored at80C, then aliquoted to 96-well plates alongside control samples. For plasma and serum, 5 mL are processed and yield sufficient tryptic
digest for fivemeasurements on the high-flow rate LC-MS platform. Sample preparation (yellow boxes): the sample preparation workflow is designed for handling
384 samples per batch (four 96-well plates). Batch effects are mitigated by using pre-aliquoted stock solution plates—prepared for whole projects and stored at
80C—that enter the workflow at different steps, as well as by using a liquid handling robot for pipetting andmixing. Sample cleanup is done with 384 samples/
batch by using 96-well solid-phase extraction plates (BioPureSPE, the Nest Group) and a liquid handler for pipetting. The hands-on time for cleanup is <2 h and
although the digestion is done overnight, the total hands-on time for the sample preparation is <3.5 h. Data acquisition (blue boxes): ultra-fast measurements of
the digested samples are facilitated in 300-s chromatographic gradients using high-flow chromatography (800 mL/min) with a short reversed phase C18 column
(50 3 2.1 mm, 1.8 mm particle size) to accelerate equilibration and washing steps. A 700 ms duty cycle, required to record sufficient data points per chro-
matographic peaks that elute at FWHMof about 3 s is achievedwith an optimized SWATH data acquisitionmethod. The theoretical throughput of data acquisition
for one mass spectrometer is 180 samples/day.
(B) Data processing (red boxes): the analysis of the highly complex short-gradient DIA data is achieved with an optimized version (1.7.10) of DIA-NN (Demichev
et al., 2020). DIA-NN is based on neural networks to enable confident peptide identification with fast gradients and achieves a throughput of >2,000 samples/day
on a conventional PC. First, a spectral library is automatically ‘‘refined’’ using the dataset in question: only detectable peptide precursors are retained, and their
reference spectra and retention times are replaced with empirically observed. Reanalysis with this refined library is then followed by batch correction and, finally,
protein quantification using MaxLFQ (Cox et al., 2014). Abbreviations: ABC, ammonium bicarbonate; DTT, dithiothreitol; IAA, iodoacetamide; FA, formic acid.
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A
C D
B Figure 2. High-Flow LC and Its Application
to Short-Gradient MS-Based Proteomics
(A) A tryptic digest of human blood plasma was
injected 10 times. The peptides were separated
with a 300 s linear water to acetonitrile chro-
matographic gradient using an Agilent 1290 In-
finity II LC system coupled to a TripleTOF 6600
mass analyzer. The TICs of the first and last in-
jection were overlaid and colored with blue and
red, respectively. The time from the start of one run
to the next was reduced to 8 min (including in-
strument overheads), which enables a throughput
of ~180 samples/day. After the 10 plasma in-
jections, water was injected and the TIC (black
line) shows no significant carryover despite the
short washing time.
(B) Extracted ion chromatograms of 5 synthetic
peptides (AETSELHTSLK [m/z 408.55, black line],
LDSTSIPVAK [m/z 519.80, orange line], ALEN-
DIGVPSDATVK [m/z 768.90, blue line], AVY-
FYAPQIPLYANK [m/z = 883.47, green line], and
TVESLFPEEAETPGSAVR [m/z 964.97741, red
line]) from a synthetic peptide mixture (Pepcal,
Sciex) as separated on the 300 s linear gradient.
Chromatograms were extracted from TOF MS
data, width = 0.1 Da.
(C) A tryptic digest of K562 human cell lines was
separated with a 20-min linear gradient ramping
from 3% ACN 0.1% FA to 36% ACN, 0.1% FA on
high-flow (800 mL/min; C18 column 50 mm 3 2.1,
column length). Peak widths at FWHM of the
eluting peptides were compared to a 20-min micro-flow run (5 mL/min; 15-cm column; Demichev et al., 2020), analyzed on the same mass spectrometer (Sciex
TripleTOF 6600).
(D) Peak capacities (gradient length divided by FWHM) for 3, 5, 10, and 20-min linear gradients (3% ACN/0.1% FA to 36% ACN/0.1% FA) on high-flow compared
with 20-min micro-flow chromatographic gradients (red dashed line).
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increased the quantification precision for serum and plasma
proteomes.
Benchmarking Acquisition Depth, Quality, and Data
Consistency in an Epidemiological Study
To assess the suitability of our high-throughput platform for
human blood plasma and serum proteomics, we generated pro-
teomes for undepleted serum samples derived from 199 random
individuals that participated in the GS epidemiological study
(Smith et al., 2013). GS is a family-based cohort of approximately
24,000 individuals in 7,000 family groups from across Scotland,
aged between 18 and 98 (Smith et al., 2013). We also included
a large number of commercial plasma (tebu-bio, 91 total) and
serum (tebu-bio, 79 total) samples as quality controls for the sam-
ple preparationworkflow, aswell as repeated injections of a single
sample every 11 samples (pooled from 32 prepared commercial
serum samples, 39 total) as a control for the LC-MS performance.
The sample preparation was done in four 96-well plates and the
experiment involved 409 non-blank injections.
For interrogating the raw data, we made use of a high-quality
spectral library (Bruderer et al., 2019) that was refined with DIA-
NN based on the actual data (Figure 1B). Upon protein extraction
and batch effect correction (STAR Methods), we assessed the
robustness and consistency of protein identification achieved
and herein illustrate the key quality parameters. The high-flow
LC setup yielded exceptional retention time stability across thewhole experiment (Figure 3A). As expected, due to the short
gradients, the total proteomic depth (total number of peptides
quantified) is lower than achieved with MS workflows that use
pre-fractionation and longer gradients with lower flow rates
and have a slower duty cycle to scan over a larger mass range.
In undepleted plasma, these typically detect 250 to 450 proteins
per injection (Bian et al., 2020; Bruderer et al., 2019; Geyer et al.,
2016a; Liu et al., 2015). However, with an average of ~270 pro-
tein groups detected per injection and 311 in total, our much
faster platform still covers most of the typical plasma proteins
(Anderson and Anderson, 2002) also seen by the other methods.
Indeed, this compendium of proteins quantified includes at
least 44 FDA-approved protein biomarkers (Table S5). More-
over, for large-scale experiments, the numbers of consistently
quantified peptides and proteins are more relevant than the
maximum number of protein groups identified, as only consis-
tent detection allows for quantitative comparison between indi-
viduals and is suitable for the development of clinical assays.
We consistently identified around 3,000 peptide precursors
(i.e., peptides ionized to a specific charge; Figure 3B) and 200
unique proteins (i.e., gene products identified with specific pro-
teotypic peptides; Figure 3C) across all 409 proteome acquisi-
tions. In total, we detected 311 protein groups, out of which 245
uniquely identified proteins were measured with 87% data
completeness and with at least five peptides. Among these,
182 unique proteins were quantified with 99% data complete-
ness (Figure 3D).Cell Systems 11, 11–24, July 22, 2020 15
Figure 3. Robustness and Quantitative Precision of the Proteomic Platform Applied to a Population-Based Epidemiological Cohort
409 serum proteomes were analyzed for characterizing 199 participants of the GS study. The sample series are composed of 39 repeat injections (‘‘QC’’), 79
serum and 91 plasma commercial sample preparation controls, and 200 serum samples derived from the 199 participants of the GS study (‘‘GS’’).
(A) Overlaid aligned retention times (Biognosys iRT scale) of all peptide identifications in the whole experiment. Median iRT standard deviation (SD) was 0.22
(relative SD = 0.0009) and correlation between the observed iRT and library iRT was 0.99995, indicating very high retention time stability.
(B and C) (B) Numbers of peptide precursors and (C) unique proteins identified in control samples.
(D) Data completeness in the whole experiment plotted against the number of proteins identified. The data completeness for all 245 unique proteins was 87%,
whereas 182 proteins were identified with data completeness 99%.
(E) PCA using consistently identified proteins (log-transformed quantities).
(F) The ‘‘serum’’ cluster on the PCA plot, with samples prepared on different 96-well plates colored differently. No bias between the plates can be detected.
(G) CV. After accounting for instrument drift, median CV values are 5.4% for replicate injections (‘‘QC’’), 7.6% for serum controls, 7.3% for plasma controls, and
25.6% for the participants’ samples.
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proteomic data using principal component analysis (PCA) (Fig-
ure 3E). The PCA data fully separate in PC1 all serum from
plasma samples, and in PC2, the control serum samples from
the GS serum samples. The difference between the GS samples
and the commercial samples might be explained by different
serum collection and/or storage procedures. Moreover, the bio-
logical variability across the randomly chosen individuals is
much higher than the technical variability (spread of GS samples
versus serum or plasma samples) and hence is detected with
high confidence by our platform. We further examined in detail
the ‘‘serum’’ cluster of points and did not detect any bias be-
tween different sample preparation plates (Figure 3F).
Finally, we evaluated the quantification precision by calcu-
lating the CV of protein quantities across the studies. Median
values obtained are 5.4% for repeat reference sample injections
(‘‘QC’’) after instrument drift correction, with high abundant pro-
teins being measured with a less than 2% CV of protein quanti-
ties (Figure S2B). Serum controls and plasma controls were
measured with 7.6% and 7.3% CV, reflecting the precision of
the entire workflow including sample preparation, acquisition,
and data analysis. These values are much lower than the biolog-
ical variation detected across the randomly chosen GS partici-
pants; when this biological variation is expressed as a CV value,
it corresponds to a variation of 25.6% (Figure 3G). The platform
hence confidently identifies biological variability in large-scale
serum proteomic experiments of randomly chosen and pre-16 Cell Systems 11, 11–24, July 22, 2020sumed healthy individuals. Indeed, to our knowledge, such
high precision values (<2% for high abundant proteins, 5.4%
CV for all proteins [in the LC-MS part of the workflow], 7.3%
for the entire workflow including sample preparation over
processing 409 proteomes) have not been achieved to date in
comparable large-scale proteomic studies.
Rapid and Precise High-Flow Rate Proteomics Identifies
Biomarkers for COVID-19
Weapplied the developedworkflow for the analysis of serumand
citrate plasma samples for two independent COVID-19 cohorts
that included patients who were among the first that were hospi-
talized at Charité Universit€atsmedizin Berlin, between March 1st
and March 26th 2020. Thirty-one SARS-CoV-2 infected patients
were included in the exploratory cohort to identify biomarkers
(Figure 4A; Table S1). 11/31 (35%) patients were female and
20/31 (65%) were male, median age was 54 years (range 21–
81). Severity of COVID-19 was graded using the WHO ordinal
outcome scale of clinical improvement (score 3 = hospitalized,
no oxygen therapy; score 4 = oxygen by mask or nasal prongs;
score 5 = non-invasive ventilation or high-flow oxygen; score
6 = intubation and mechanical ventilation; score 7 = ventilation
and additional organ support) (World Health Organization,
2020) (Table S2). Four patients (13%) died from COVID-19, and
4 patients remain hospitalized at the time of writing. All other pa-
tients have been discharged in good health from hospital. Suc-





Figure 4. Protein Signatures Indicate Clinical Severity in COVID-19
(A) Study design. 199 random individuals from theGS studyweremeasured to assess the performance of the platform and to obtain a population baseline. Protein
responses based on COVID-19 severity were obtained from a cohort of 31 hospitalized SARS-CoV-2 infected patients. Severity of COVID-19 was graded using
the WHO ordinal outcome scale of clinical improvement (World Health Organization, 2020).
(B) PCA based on proteins found differentially expressed depending on COVID-19 severity. Median quantities across all time points were calculated for each
patient and 29 proteins without missing values were used to generate the PCA plot (quantities were standardized). Cases with the severity ‘‘3’’ on the WHO scale
(hospitalized, no oxygen therapy) are well separated from cases with the severity ‘‘7’’ along the first principle component, with ‘‘4’’–‘‘6’’ cases in between.
(legend continued on next page)
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OPEN ACCESS Articleand 17 further patients suffering from COVID-19, was recruited
at the same hospital and used for validation of the biomarkers
discovered (Table S1).
Because of the rapid action required in an early phase of a
pandemic, we sampled depending on the first patients hospital-
ized (i.e., there was no other inclusion criteria than a hospitaliza-
tion due to a SARS-CoV-2 infection). Such a cohort certainly
differs from a long-term planned epidemiological cohort such
as the GS study. With samples collected as part of the hospital
routine by different medical professionals, the level of sample
variability is expected to be higher. Moreover, it is difficult to
assemble a control cohort that is matched for the key confound-
ing factors, like age. Nonetheless, our proteomic platform
yielded only slightly inferior values compared to the ideal-case
scenario of the GS study. In the exploratory cohort, which
included 104 serum samples obtained from the 31 of the earliest
COVID-19 patients, we quantified 297 protein groups among
which 229 unique proteins were detected with 75% data
completeness. We surmise that this somewhat lower data
completeness was caused by the massive changes in levels of
a number of proteins upon severe SARS-CoV-2 infection as
well as by the decrease in total serum protein content, also
observed previously in patients hospitalized in ICU units (Nie
et al., 2020). To account for this biological limitation, we applied
very strict filtering to the dataset, namely, we only tested for dif-
ferential abundance of proteins which had at least five different
peptide precursors identified at least in one of the acquisitions.
We identified 37 protein groups with either increasing or
decreasing levels, depending on the severity of the disease
(0.05 significance, multiple testing corrected, Theil-Sen test
against the WHO severity score; see STAR Methods for testing
methodology) (Figure S7). Next, to validate the biomarkers, we
processed the validation cohort (Table S1) and recorded 96 pro-
teomes in triplicates for 15 healthy volunteers and 17 COVID-19
patients (Table S1). The experiment quantified 319 protein
groups among which 248 unique proteins were detected with
85%data completeness. Despite being conducted on a different
matrix (citrate plasma), this independent study confirmed 27 of
the protein groups with either increasing or decreasing levels
(A1BG, ACTB;ACTG1, ALB, APOA1, APOC1, C1R, C1S, C8A,
CD14, CFB, CFH, CFI [complement factor I], CRP, FGA, FGB,
FGG [fibrinogen alpha, beta, and gamma chains], GSN, HP,
ITIH3 [inter-alpha-trypsin inhibitor heavy chain 3], ITIH4 [inter-
alpha-trypsin inhibitor heavy chain 4], LBP, LGALS3BP, LRG1,
SAA1 [serum amyloid A1], SAA1;SAA2 [serum amyloid A1 and
A2 protein group], SERPINA10, TF; 0.05 significance, multiple
testing corrected, Figure S4). This set of proteins thus represents
potential biomarkers of disease severity. Out of the remaining 10(C) Heatmap shows protein signatures that report on COVID-19 severity. Visualiz
Black ‘‘squares’’ indicate missing values. Patients labeled with an asterisk (*) had
(D) Proteins upregulated (top panel) and downregulated (lower panel) dependin
Scotland), as well as the population spread of the protein abundance in 199 rand
As the absolute quantities from the COVID-19 andGS studies cannot be compared
assessment of the population spread, by normalizing by the median of GS quant
normalized valueswere used for illustration purposes only and not used for testing
median (middle) and the whiskers extend to the most extreme data point, which
gulated with increasing severity of COVID-19: A1BG, ACTB;ACTG1, C1R (compl
(monocyte differentiation antigen CD14), CFB (complement factor B), CFH (co
LGALS3BP, LRG1, SAA1, SAA1;SAA2, and SERPINA10; proteins downregulated
18 Cell Systems 11, 11–24, July 22, 2020proteins, 9 (AGT [Angiotensinogen], AZGP1 [Zinc-alpha-2-
glycoprotein], C2 [Complement C2], C7 [Complement compo-
nent C7], C8B [Complement component C8 beta chain], CLU
[Clusterin], CPN1 [Carboxypeptidase N catalytic chain], PLG
[Plasminogen], and VTN [Vitronectin]) did not reach statistical
significance in the smaller validation group, whereas the
IGHG2;IGHG3 (Immunoglobulin Heavy Constant Gamma 2 and
3) protein group showed the opposite trend. We illustrate the
quantitative variability of the validated biomarkers for COVID-
19 severity on a heatmap (Figure 4C) and as boxplots (Figures
4D) as well as summarize their potential connection to COVID-
19 in Table S3.
To exclude the possibility that concentration changes in these
markers are due to frequent confounders, like age, we have
plotted the variability of the same proteins in the GS cohort,
with age spanning from 37 to 79, on samples that have been
collected before the COVID-19 outbreak. We note that for iden-
tified proteins the change between mild and severe COVID-19
substantially exceeds the variation seen in the general popula-
tion (Figure 4D). Moreover, plotting the protein abundance
values against the age did not reveal significant correlations
across the GS population baseline (Figure S8).
A PCA categorizes the individuals according to the severity of
COVID-19 (Figure 4B). This shows that plasma proteomes, as
measured with our platform, suit as clinical classifiers. Moreover,
we illustrate the concentration changes of the biomarkers vali-
dated in the control cohort, upon grouping of the patients ac-
cording theWHO severity criteria, ranging from scale 3 (hospital-
ized, no oxygen therapy) to the most critical (scale 7) in a
heatmap (Table S1 for the grading of each patient), which graph-
ically illustrates how level changes in these proteins reflect a pro-
gression from mild to severe COVID-19 (Figure 4C). Of note,
WHO criteria consider patients up and including category 4 as
‘‘mild,’’ a classification that orients on the situation, that until
this point, clinical care does not include invasive treatments
that are difficult to provide, like intubation. However, our prote-
ome data indicate the most substantial changes between cate-
gories 3 and 4, upon which a patient is put on oxygen supply.
Our unbiased analysis hence indicates that at a molecular level,
the requirement of oxygen supply coincides with a progression
to severe disease.
Case studies indicate the clinical utility of the proteome signa-
tures. First, two patients (#13 and #32) in the group of critical pa-
tients, which later died from COVID-19, clearly clustered in the
heatmap and indeed had one of themost pronounced proteomic
signatures (Figure 4C), implying that proteomics bears the po-
tential to support predictions of clinical trajectories. Moreover,
two case studies indicate that systematically recordedation was performed using the ComplexHeatmap R package (Gu et al., 2016).
a fatal outcome of the disease.
g on COVID-19 severity (WHO grade; SS, standard serum; GS, Generation
omly selected individuals of an independent cohort (Generation Scotland; GS).
directly (samples were obtained in a different manner), we simplified the visual
ities to the median of WHO grade 3 (no oxygen support) COVID-19 cases (the
for statistical significance). The boxes show first and third quartile aswell as the
is no more than 1.5 times the interquartile range from the box. Proteins upre-
ement C1r), C1S (complement C1s), C8A (complement C8 alpha chain), CD14
mplement factor H), CFI, CRP, FGA, FGB and FGG, HP, ITIH3, ITIH4, LBP,
with increasing severity of COVID-19: ALB, APOA1, APOC1, GSN, and TF.
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applied clinical assays. When we first obtained the dataset,
two individuals (patients 4 and 6) initially clinically assessed as
severe (Kurth et al., 2020) clustered with patients that suffered
from the mild form of COVID-19 (Figure S3). These results trig-
gered a retrospective assessment, which revealed that patient
4 turned out to be suffering from type B influenza rather than a
SARS-CoV-2 infection, whereas patient 6 was classified as se-
vere due to recent chemo-immunotherapy due to a hematolog-
ical malignancy, applied just ten days before his COVID-19-
related hospitalization. We have, as a consequence, excluded
patient 4 from the COVID-19 dataset (all results shown in
Figure 4). Both clinical case findings indicate however a high
prognostic precision of the proteomic biomarker signatures
and demonstrate that proteomes may very well outperform con-
ventional clinical assays: no current clinical assays would have
identified this type of outliers in the clinical assessment of the
two individuals.
Proteome Signatures of Inflammation and Acute-Phase
Response in Severe COVID-19
Each virus triggers its own host response, with some effectively
evading the innate immune system (Kikkert, 2020). Some viral in-
fections are hence causing only minor inflammatory responses,
for example, HIV or many herpesviruses (Beachboard and
Horner, 2016; Ongrádi, 2016; Sauter and Kirchhoff, 2016). Other
viruses elicit dramatic inflammation and dysregulated coagula-
tion, for example hemorrhagic fevers, e.g., Ebola virus (Baseler
et al., 2017). The host immune response to SARS-CoV-2 is so
far largely unknown. We detected consistent activation of both
the classical complement pathway (C1R, C1S, and C8A) as
well as the alternative pathway factor B (CFB) and the comple-
ment modulators: factors I (CFI) and H (CFH). Other differentially
expressed proteins included the common acute-phase reac-
tants, such as C-reactive protein (CRP) (upregulated), albumin
(ALB) (downregulated), or serum amyloid proteins SAA1 and
SAA2 (upregulated).
We observed upregulation of a number of proteins implicated
in IL-6 signaling (Figure 4; Table S3). In addition to SAA1 and
SAA2, these include inter-a-trypsin inhibitor heavy chain 4
(ITIH4), which plays an important role in extracellular matrix orga-
nization and is implicated in inflammation (Bost et al., 1998; Yang
et al., 2012), HP, an acute-phase response protein (Jain et al.,
2011), LRG1, a promoter of cell proliferation and angiogenesis,
implicated in local inflammation and fibrosis (Honda et al.,
2017), monocyte differentiation antigen CD14, primarily involved
in bacterial LPS recognition (Kielian and Blecha, 1995), and the
LBP, as well as LGALS3BP, a pro-inflammatory factor, which
is known to induce IL-6 expression (Silverman et al., 2012).
Thus, the proteomic approach surprisingly revealed a very IL-
6-centered response. With the caveat that the depth of plasma
proteomes is limiting, we found little evidence of involvement
of other common inflammatory mediators (e.g., tumor necrosis
factor (TNF), interferon (IFN) gamma, and their targets). Our
study thus puts further emphasis on the importance of studying
IL-6 function in relationship to new proteins and as therapeutic
and diagnostic candidates.
We also observe upregulation of fibrinogen, a coagulation fac-
tor, and SERPINA10, an inhibitor of the F10a coagulation factor,further highlighting the importance of coagulation in SARS-CoV-
2 infection, established by previous observations of elevated
coagulation in severe COVID-19 cases (Zhou et al., 2020a).
A parallel study by (Shen et al., 2020) used a more conven-
tional and time consuming (1203 pre-fractionation consoli-
dated in 40 fractions with TMT-16 plex) proteomics method
to characterize plasma samples from 99 study participants,
including 46 samples from patients with COVID-19 diagnosed
in China. Despite the different cohorts and different technolo-
gies used, the proteomes implicate similar biological mecha-
nisms in the differentiation of mild, severe, or critical disease
progression. Many of the proteins that differentiate the groups
in both studies belong to the complement system, acute-
phase, and inflammatory response. For example, both studies
agree with independently conducted clinical investigations on
a number of differentially expressed proteins, in particular,
ALB, the complement factors, serum amyloid proteins, ITIH3
and ITIH4 (Nie et al., 2020; Shen et al., 2020). Despite these
similarities, we note important differences. For instance, we
cannot confirm the downregulation of pro-platelet basic
protein (PPBP) and platelet factor 4 (PF4) in severe COVID-
19 as highlighted by Shen et al. We can offer several potential
explanations. We note that different SARS-CoV-2 clades
might exhibit different degrees of pathogenicity (Yao et al.,
2020) and thus elicit different physiological responses, espe-
cially in different populations. However, when examining
the response of PF4 and PPBP at the peptide level, we
discovered that although several peptides maintain a relatively
stable level, other PF4- and PPBP-specific peptides increase
or decrease in concentration (Figure S5). This situation
might indicate that instead of being differentially expressed,
PF4 and PPBP might be differentially post-translationally
modified.
Plasma Proteomes Provide Insights into the Virulence
Mechanisms and Potential Therapeutic Targets for
COVID-19
Extensive worldwide efforts have been directed recently into
finding drug targets for COVID-19 treatment. As most of the
damage associated with severe SARS-CoV-2 infection ap-
pears to be indirect and caused by excessive inflammation
in the lungs, it is of crucial importance to seek opportunities
not only to target the pathway of entry and the replication
mechanism of the virus but to also identify and examine the
possibilities for targeting host factors responsible for harmful
inflammatory responses to both alleviate the severity of the
infection and to reduce the chance of long-lasting complica-
tions (Huang et al., 2020). Some preliminary results in that di-
rection appear promising. For example, pro-inflammatory
signaling via IL-6 has been determined to be a marker of se-
vere COVID-19 (Chen et al., 2020; Ruan et al., 2020) and pre-
liminary results on the inhibition of IL-6 receptor (IL-6R) with
tocilizumab seem to indicate clinical improvement (Coomes
and Haghbayan, 2020). Here, we discovered several proteins
that are differentially expressed with the severity of COVID-19
that are linked to IL-6-mediated proinflammatory cytokine
signaling: (1) the CD14-LBP LPS recognition system, (2) upre-
gulation of LRG1, an angiogenesis and anti-apoptotic factor
associated with inflammation, and (3) upregulation of theCell Systems 11, 11–24, July 22, 2020 19
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OPEN ACCESS ArticleLGALS3BP, an inducer of IL-6. Below, we discuss the poten-
tial significance of these findings.
Coronaviruses are known to actively disrupt the host
immune response (Enjuanes et al., 2016). For example, their
papain-like proteases (PLPs) act as interferon antagonists
(Niemeyer et al., 2018), causing delayed type-I interferon
response, macrophage-mediated inflammation, and lung
damage (Channappanavar et al., 2016). Here, we observed
upregulation of both monocyte differentiation antigen CD14
(~2.73) and LBP (~3.93) in severe COVID-19. As the
response to bacterial LPS is one of the primary functions of
both CD14 and LBP, which can act in complex to sensitize
toll-like receptor-mediated LPS recognition (Ranoa et al.,
2013), this observation reflects the dysregulation of the innate
immune response by SARS-CoV-2, leading to the activation of
the anti-bacterial defense and sensitization to LPS, thus
contributing to excessive inflammation, with effects likely
more pronounced in case of a concomitant secondary bacte-
rial infection. Interestingly, CD14 and LBP upregulation has
been observed in viral pneumonia before (Van Gucht et al.,
2005), while CD14 is one of the primary mediators of lung
inflammation (Anas et al., 2010). Of note, the glycosylphos-
phatidylinositol (GPI)-anchored form of CD14 is primarily dis-
played by monocytes and macrophages (Marcos et al.,
2010), while the proportion of CD14+CD16+ inflammatory
monocytes in the peripheral blood increases along with
COVID-19 severity (Zhou et al., 2020b). At the same time,
IL-6 induces soluble CD14 production in the liver (Bas et al.,
2004) as well as, along with other cytokines, release of
CD14 from monocytes upon their activation (Shive et al.,
2015). Given that CD14 is a potent activator of pro-inflamma-
tory cytokine signaling (Zanoni and Granucci, 2013), it might
present a potential therapeutic target for COVID-19.
LRG1 is another pro-inflammatory factor induced by IL-6
(Shirai et al., 2009), which is known to promote angiogenesis
and cell proliferation, while inhibiting apoptosis (Meng et al.,
2016; Naka and Fujimoto, 2018; Wang et al., 2013). Some
recent findings indicate its role in promoting skin fibrosis
and lung fibrosis in transforming growth factor beta (TGF-b)-
mediated fashion (Gao et al., 2019; Honda et al., 2017). Given
the previously reported association of the Middle East respira-
tory syndrome (MERS) infection with lung fibrosis (Zhao et al.,
2008) and emerging reports (British Thoracic Society, 2020) of
lung fibrosis in a substantial proportion of COVID-19 survivors,
we hypothesize that the ~2.13 elevation of serum LRG1
levels we observe in critical COVID-19 cases in comparison
with the mild cases might indicate the increased risk of
fibrosis, highlighting LRG1 as yet another potential therapeu-
tic candidate for COVID-19 treatment. Furthermore, we de-
tected about ~3.43 upregulation of LGALS3BP, which is
known to induce the expression of IL-6 by stromal cells in ga-
lectin-3-dependent manner (Silverman et al., 2012). Of note,
Galectin-3 has long been considered an attractive drug target
in combating various forms of TGF-b-mediated fibrosis and
pathological inflammatory conditions (Brinchmann et al.,
2018; Mackinnon et al., 2012; Shen et al., 2018; Yu et al.,
2013). Inhibition of galectin-3-mediated signaling pathways
hence represents another potential therapeutic target against
COVID-19.20 Cell Systems 11, 11–24, July 22, 2020Tissue Injury and Dysregulation of Modulators of
Inflammation
We report substantially decreased (~2.63) levels of GSN (Fig-
ures 4C and 4D). Plasma GSN is a part of the extracellular actin
scavenger system (EASS), which removes toxic F-actin fila-
ments that have been released from necrotic cells to the blood-
stream (Piktel et al., 2018). Low levels of plasma GSN are asso-
ciated with inflammation: it is believed that GSN is recruited to
the sites of tissue injury to handle the released actin, depleting
its plasma levels. Interestingly, we do observe the increase in
serum actin concentration (beta and gamma-1 actin, ~23),
indicative of tissue injury (DiNubile, 2008), which could explain
the GSN depletion from the blood. Importantly, plasma GSN is
a powerful modulator of inflammation, which carries a protective
function (DiNubile, 2008; Li et al., 2012). Low plasma GSN is a
marker of poor prognosis in various pathological conditions,
including diabetes (Khatri et al., 2014), cancers (Asare-Werehene
et al., 2019; Stock et al., 2015), and sepsis (Lee et al., 2007), lead-
ing to suggestions and animal tests for its therapeutic use. Going
forward, it will be important to assess GSN levels in at-risk pop-
ulations for severe COVID-19, e.g., patients with diabetes. Of
note, treatment with GSN has been observed to decrease IL-6
levels in mice (Cheng et al., 2017) and has been suggested to
promote epithelial repair (Wittmann et al., 2018). The develop-
ment of therapies to stabilize the GSN levels could hence be of
direct therapeutic value for treating COVID-19.
Notably, we observed a decrease in the expression levels of
APOA1 (APOA1; ~33). APOA1 is a major component of the
high-density lipoprotein (HDL) complex, which is a modulator
of innate immune response and inflammation (Fotakis et al.,
2019; Gordon et al., 2011; Macpherson et al., 2019; White
et al., 2017). We also observe decreased levels of APOC1
(~3.23), a component of several lipoprotein complexes (Fuior
and Gafencu, 2019). Based on the GS study, we note that the
serum levels of APOA1 are correlated with those of HDL choles-
terol (Figure S6). Although decreased APOA1 levels have been
observed in systemic inflammatory response (Kumaraswamy
et al., 2012; Sirniö et al., 2017), including in COVID-19 (Nie
et al., 2020), a potential explanation of the downregulation we
observe here would also be provided, if naturally lower APOA1
and hence a different metabolic condition of the individual
were associated with a higher risk of severe SARS-CoV-2 dis-
ease progression.
In conclusion, SARS-CoV-2, SARS, and MERS constitute a
class of emerging coronaviruses of high public health concern.
It is likely that other viruses will emerge in the future for which
at time of outbreak insufficient biochemical knowledge will be
available to identify biomarkers and to define point-of-care clin-
ical classifiers. Serum and plasma proteomics can present valu-
able and unbiased information about disease progression and
therapeutic candidates, without prior knowledge about the etiol-
ogies and biomolecules involved. We present a workflow for
rapid and large-scale clinical proteomics that is re-designed in
comparison to previous platforms. The sample preparation
workflow scales to high sample numbers, enables high quantifi-
cation precision, and reduces batch effects for large-scale and
longitudinal studies, while the data acquisition and processing
workflow is able to exploit the advantages of high-flow chroma-
tography in short-gradient proteomics. Our platform improves
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regulated laboratories, as it builds on ISO13485 standardization
as a reference. We demonstrate a quantification precision and
acquisition robustness that, to our knowledge, has not previ-
ously been shown in large-scale proteomic experiments. We
then applied the technology to a cohort of early hospitalized
cases of the SARS-CoV-2 pandemic. We identify a series of pro-
teins that are differentially expressed depending on the severity
of COVID-19 and demonstrate the potential of proteome signa-
tures to act as clinical classifiers. The proteome signatures cap-
ture the host response to COVID-19 infection, highlighting the
role of complement factors, the coagulation system, and indi-
cate a high specificity of several inflammation modulators as
well as pro-inflammatory signaling both upstream and down-
stream of IL-6. The proteomic signatures and biomarkers identi-
fied pave the way for the development of routine assays to
support clinical decision making, as well as provide hypotheses
about potential COVID-19 therapeutic targets.
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Human Serum Sigma-Aldrich Cat# S7023-50MB
Human Plasma (EDTA, Pooled Donor) Genetex Cat# GTX73265
Human Serum, Normal off-the-Clot, Frozen tebu-bio Cat# 088SER
Human Recovered Plasma, Pooled- frozen
K2EDTA
tebu-bio Cat# 088SER-PLP200-EDTA
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Mass Spec-Compatible Human Extract Promega Cat# V6951
Retention time peptides Biognosys iRT kit Biognosys Cat# Ki-30002-b
MS synthetic peptide calibration kit SCIEX Cat# 5045759
Deposited Data
Raw data (commercial plasma and serum
control samples within the GS study)
This study Pride:PXD018874
Software and Algorithms
Proteomics data analysis via Deep Neural
Networks, DIA-NN





PeakView (Version 2.2) SCIEX N/A
DIA-NN R package Demichev et al., 2020 https://github.com/vdemichev/diann-
rpackage
ComplexHeatmap R package Gu et al., 2016 https://github.com/jokergoo/
ComplexHeatmap
EnvStats R package Millard, 2014 https://CRAN.R-project.org/
package=EnvStats
Zoo R package https://CRAN.R-project.org/package=zoo
Other
Zorbax RRHD Eclipse Plus 95A C18, 2.1 x
50mm, 1.8 um, 1200 bar
Agilent Cat# 959757-902
BioPureSPE Macro 96-Well,
100mg PROTO 300 C18
The Nest Group, Inc. HNS S18V-L
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Markus
Ralser (markus.ralser@charite.de).
Materials Availability
This study did not generate new materials.
Data and Code Availability
The raw data of the acquired commercial plasma and serum control samples within the GS study have been deposited to the Pro-
teomeXchange Consortium via PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier Pride:PXD018874. Ac-
cording to the terms of consent for GenerationScotland participants, access to individual-level data (omics and phenotypes) must be
reviewed by theGSAccess Committee. Applications should bemade to access@generationscotland.org. TheDIA-NN software suite
and DiaNN R package are open source and are freely available for download at https://github.com/vdemichev/DiaNN and https://
github.com/vdemichev/diann-rpackage respectively.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical Samples of COVID-19 Patients
Sampling was performed as part of the Pa-COVID-19 study, a prospective observational cohort study assessing pathophysiology
and clinical characteristics of patients with COVID-19 at Charité Universit€atsmedizin Berlin (Kurth et al., 2020). All patients with
SARS-CoV-2 infection proven by positive PCR from respiratory specimens and willing to provide written informed consent are
eligible for inclusion. Exclusion criteria are refusal to participate in the clinical study by patient or legal representative or clinical
conditions that do not allow for blood sampling. The study assesses epidemiological and demographic parameters, medical history,
clinical course, morbidity and quality of life during hospital stay of COVID-19 patients. Moreover, serial high-quality bio-sampling con-
sisting of various sample types with deep molecular, immunological and virological phenotyping is performed. Treatment and med-
ical interventions follow standard of care as recommended by current international and German guidelines for COVID-19. Severity of
illness in the present study follows the WHO ordinal outcome scale (Tables S1 and S2). The Pa-COVID-19 study is carried out ac-
cording to the Declaration of Helsinki and the principles of Good Clinical Practice (ICH 1996) where applicable and was approved
by the ethics committee of Charité- Universit€atsmedizin Berlin (EA2/066/20).
Generation Scotland Study
199 serum samples from random individuals that participated in the Generation Scotland (GS) epidemiological study (Smith et al.,
2013) were used. GS is a family-based cohort of approximately 24,000 individuals in 7,000 family groups from across Scotland,
aged between 18 and 98 (Smith et al., 2013). All components of Generation Scotland received ethical approval from the NHS Tayside
Committee onMedical Research Ethics (RECReferenceNumber: 05/S1401/89). All participants provided broad and enduringwritten
informed consent for biomedical research. Generation Scotland has also been granted Research Tissue Bank status by the East of
Scotland Research Ethics Service (REC Reference Number: 15/0040/ES), providing generic ethical approval for a wide range of uses
within medical research. This study was performed in accordance with the Helsinki declaration.
METHOD DETAILS
Plasma and Serum Sample Preparation
The protocol was designed for preparing four 96-well plates in parallel and that a single person using a single liquid handling unit can
start and complete every day up to two 4-plate batches. The total hands-on time per batch is 3.5 hrs only and the workflow fits within
the 8hr time-window. All liquid transfer and mixing except the addition of serum/plasma to the denaturing buffer was carried out by
the liquid handling robot, either a Beckman Coulter Biomek NXp (Crick laboratory) or Biomek i7 liquid handling robot (Charité Uni-
versit€atsmedizin Berlin). There are slight differences between the protocols due to the two different laboratories. To our knowledge,
these have no detectable influence on the results. Where applicable these differences are indicated as ‘‘Biomek NXp’’ or ‘‘Biomek i7
protocol’’, respectively.
Before starting the sample preparation, 96-well plates were prefilled with Trypsin (12.5ml, 0.1mg/ml solution; four plates/batch),
denaturation/reduction buffer (55ml 8M Urea, 100mM ammonium bicarbonate (ABC) and 4.5mM dithiothreitol (DTT) (Biomek NXp
protocol) or 50mM DTT (Biomek i7 protocol); four plates/batch) and iodoacetamide (IAA) (100mM, > 20 ml, one plate/batch) and
stored sealed at -80C until the day of the experiment. These stock solutions are thawed/brought to room temperature just before
adding them to the sample, which prevents evaporation.
5ml of thawed serum/plasma samples were transferred to the pre-made denaturation/reduction stock solution plates. Subse-
quently the plates were centrifuged for 15s at pulse setting (Eppendorf Centrifuge 5810R), mixed and incubated at 30C for 60 mi-
nutes. The mixing in this step was done either 30s at 1000rpm on a Thermomixer (Eppendorf Thermomixer C) (Biomek NXp protocol)e2 Cell Systems 11, 11–24.e1–e4, July 22, 2020
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incubated in the dark at 23C for 30 minutes before dilution with 100mM ABC buffer (340ml). 220ml of this solution was transferred to
the pre-made trypsin stock solution plate and incubated at 37C for 17 h (Memmert IPP55 incubator). The trypsin/total protein ratio
was ~1/40 as this provided high and reproducible identification numbers (Figure S2D). The digestion was quenched by addition of
formic acid (10% v/v, 25ml). The digestion mixture was cleaned-up using C18 96-well plates (BioPureSPE Macro 96-Well, 100mg
PROTO C18, The Nest Group). For the solid phase extraction, 1 minute of centrifugation at the described speeds (Eppendorf Centri-
fuge 5810R) was used to push the liquids through the stationary phase and the liquid handler was used to pipette the liquids onto the
material in order to make four 96-well plates/batch feasible. The plates were conditioned with methanol (200ml, centrifuged at 50g),
washed twice with 50%ACN (200ml, centrifuged at 150g and flow through discarded), equilibrated twice with 0.1% FA (200ml, centri-
fuged at 150g and flow through discarded). Then 200ml of digested and quenched samples were loaded (centrifuged at 150g),
washed twice with 0.1% FA (200ml, centrifuged at 150g). After the last washing step, the plates were centrifuged another time at
200g before the peptides were eluted in 3 steps with 110ml 50% ACN (200g) into a collection plate (1.1ml, Square well, V-bottom).
Collected material was completely dried on a vacuum concentrator (Eppendorf Concentrator Plus (Biomek NXp protocol) or Fisher
Scientific, SPD300P1 (Biomek i7 protocol) and redissolved in 50ml 1% ACN, 0.1% formic acid (Biomek NXp protocol) or 50ml 0.1%
formic acid (Biomek i7 protocol), then stored at -80C until data acquisition. The samples for the SARS-CoV-2 studies were analysed
without freezing. QC samples for repeat injections were prepared by pooling commercial serum samples and were spiked with iRT
peptides (Biognosys).
Liquid Chromatography-Mass Spectrometry Setup
Liquid chromatography was established on two complementary and exchangeable ultra-high-pressure high-flow LC-MS systems,
an Agilent 1290 Infinity II (Crick laboratory) andWaters H-Class (Charité Universit€atsmedizin Berlin) system, both coupled to a Triple-
TOF 6600 mass spectrometer (SCIEX) equipped with IonDrive Tubo V Source (Sciex). In both cases, the peptides were separated in
reversed phase mode using a C18 ZORBAX Rapid Resolution High Definition (RRHD) column 2.1mm x 50mm, 1.8mm particles at a
column temperature of 30C. A linear gradient was applied which ramps from 3%B to 36%B in 5 minutes (Buffer A: 0.1% FA; Buffer
B: ACN/0.1% FA) with a flow rate of 800ml/min. For washing the column, the organic solvent was increased to 80% B in 0.5 minutes
and was kept for 0.2 minutes at this composition before going back to 1% B in 0.3 min. The equilibration times were 2.8 minutes
(Water H Class protocol) or 4.2 minutes (Agilent Infinity II protocol). Data was acquired in high sensitivity mode and the amount of
total proteins injected was 5mg (GS study) and 10mg (SARS-CoV-2). The sample load was optimised (Figure S2A) and is a balance
between how frequently one needs to clean the instrument and the identification numbers. The DIA/SWATH method consisted of
an MS1 scan from m/z 100 to m/z 1500 (20ms accumulation time) and 25 MS2 scans (25ms accumulation time) with variable pre-
cursor isolation width covering the mass range from m/z 450 to m/z 850 (Table S6). Ion source gas 1 (nebulizer gas), ion source
gas 2 (heater gas) and curtain gas were set to 50, 40 and 25 respectively. The source temperature was set to 450C and the ion spray
voltage to 5500V.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mass Spectrometry Data Processing, Batch Correction and Quality Control
The raw data were processed using DIA-NN 1.7.10 in the ‘‘robust LC (high precision)’’ mode with RT-dependent median-based
cross-run normalisation enabled. MS2 and MS1 mass accuracies were set to 20 and 12 ppm, respectively, and scan window size
set to 6. Although DIA-NN can optimise such parameters automatically, we fixed them to these values to ensure comparability.
For all the experiments, we used a project-independent public spectral library (Bruderer et al., 2019). Human UniProt (UniProt Con-
sortium, 2019) isoform sequence database (3AUP000005640) was used to annotate the library. The library was first automatically
refined based on the dataset in question at 0.01 global q-value (using the ‘‘Generate spectral library’’ option in DIA-NN). DIA-NN per-
forms such refinement by finding the highest-scoring identification for each library precursor, across all runs in the experiment, and
then replacing the library data with the empirically observed spectrum and retention time. The purpose of the refinement step is
twofold: (i) retain only those peptide precursors in the library that are detectable in the experiment of interest; (ii) make sure that
the library spectra and retention times are optimised specifically for the experimental setup in question, thus improving identification
performance. The refined library was then used to reanalyse the data. The resulting report was stringently filtered at 0.01 precursor-
level q-value, 0.005 precursor-level library q-value and 0.05 protein group-level q-value. Intra-batch correction was performed for
each peptide precursor separately: based on repeat injection controls in ‘‘GS’’ and sample preparation controls in the coronavirus
cohorts. Log-transformed peptide precursor quantities were adjusted using linear regression (‘‘GS’’) or running median smoothing
(coronavirus cohorts). Linear regression was applied only for at least 10 data points. If the p-value for non-zero slope was below
0.01, the slope multiplied by the centered injection number (i.e. the injection number in the given run minus its mean value in all
runs) was subtracted from the precursor quantities for all runs. Running median smoothing was performed in two steps using the
‘runmed’ function with the algorithm set to ‘Stuetzle’. First, a 5-point running median smoothing was performed on the quantities
in the control samples, to remove outliers. Second, interpolation of the resulting values to all runs was performed using the ‘na.ap-
prox’ function (with ‘rule’ set to 2) from the ‘zoo’ R package. Finally 41-point running median smoothing was applied. Protein quan-
tification was performed using the MaxLFQ algorithm (Cox et al., 2014) as implemented in the diann R package (https://github.com/
vdemichev/diann-rpackage, version 1.0, commit ‘‘eb4607a’’). Data completeness was defined as the proportion of non-missingCell Systems 11, 11–24.e1–e4, July 22, 2020 e3
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standard deviation divided by its empirical mean. PCA analysis was always performed only on ubiquitously identified proteins: impu-
tation was not used.
Differential Expression Analysis
In the exploratory cohort, differential expression was tested only for proteins quantified using at least five peptide precursors in one of
the acquisitions. Further, protein groups were quantified using only precursors detected in at least 10% of patient samples (both co-
horts). As we were specifically interested in proteins which could serve as biomarkers of COVID-19 severity, the test was performed
using the Kendall’s Tau test for the Theil-Sen trend estimator (as implemented in the EnvStats R package (Millard, 2014)) against the
disease severity as classified according to the WHO ordinal scale (Table S1). The input for the test was obtained by calculating, for
each patient, median protein levels across the timepoints or replicatesmeasured (Table S4 for timepoint information). Multiple testing
correction was performed using the Holm-Bonferroni method for FWER control, as implemented in the p.adjust R function, and the
significance threshold was set to 0.05. The choice of a nonparametric test (Theil-Sen) was dictated by the fact that such widespread
methods as ANOVA or linear regression are only valid under the assumption of Gaussian errors with the same variance across all
conditions. In the case of this dataset, however, we observed very significant differences in the variance, e.g. many proteins
seem a lot more variable between patients with severe and critical COVID-19 than mild COVID-19. For such a situation a nonpara-
metric test is ideal: although it would typically have less power (less proteins detected as differentially expressed), the p-values pro-
duced are reliable.
Chromatographic Peaks Full Width at Half Maximum (FWHM) Estimations
Median peak FWHM was estimated using Spectronaut 13 (version 13.12.200217.43644; Biognosys). Only precursors ubiquitously
identified in all runs (3 minutes, 5 minutes, 10 minutes and 20-minute high-flow as well as with the 20-minute micro-flow run) and
with a q-value of < 0.001 were considered (804 precursors total).
Total Ion and Extracted Ion Chromatograms
Total ion chromatograms and extracted ion chromatograms were generated with the PeakView software (Version 2.2, SCIEX), ex-
ported and plotted in R (R core team, www.R-project.org).e4 Cell Systems 11, 11–24.e1–e4, July 22, 2020
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Table  S1.  Scoring  of  exploratory  and  validation  COVID-19  cohorts .   
 
 
Exploratory  Cohort  
 








Age   Sex   Outcome  
1   3   mild   mild   21   m   discharged  
2   3   mild   mild   31   f   discharged  
3   3   mild   mild   45   m   discharged  
10   3   mild   mild   50   f   discharged  
18   3   mild   mild   60   f   discharged  
19   3   mild   mild   52   m   discharged  
23   3   mild   mild   44   f   discharged  
27   3   mild   mild   40   f   discharged  
28   3   mild   mild   64   m   discharged  
34   3   mild   mild   47   m   discharged  
35   3   mild   mild   37   f   discharged  
37   3   mild   mild   78   m   discharged  
4*       severe*   37   m    
6   3   mild   severe   24   m   discharged  
5   4   mild   severe   71   m   discharged  
7   4   mild   severe   32   m   discharged  
24   4   mild   severe   64   m   discharged  
29   4   mild   severe   53   m   discharged  
11   5   severe   severe   61   m   discharged  
16   5   severe   severe   78   m   still  hospitalized   
22   5   severe   severe   62   m   discharged  
26   5   severe   severe   56   f   discharged  
12   6   severe   critical   75   m   discharged  
20   6   severe   critical   54   f   discharged  
21   6   severe   critical   52   m   discharged  
8   7   severe   critical   63   m   still  hospitalized  
9   7   severe   critical   80   f   still  hospitalized  
13   7   severe   critical   71   m   death  
14   7   severe   critical   81   m   death  
15   7   severe   critical   54   m   death  
25   7   severe   critical   62   f   still  hospitalized   
32   7   severe   critical   50   f   death  
 








Age   Sex   Outcome  
HD-1   0   uninfected   healthy   27   f    
HD-2   0   uninfected   healthy   23   m    
HD-3   0   uninfected   healthy   34   f    
HD-4   0   uninfected   healthy   31   f    
HD-5   0   uninfected   healthy   30   m    
HD-6   0   uninfected   healthy   41   f    
HD-7   0   uninfected   healthy   24   f    
HD-8   0   uninfected   healthy   27   m    
HD-9   0   uninfected   healthy   30   f    
HD-10   0   uninfected   healthy   34   f    
HD-11   0   uninfected   healthy   42   m    
HD-12   0   uninfected   healthy   30   f    
HD-13   0   uninfected   healthy   33   f    
HD-14   0   uninfected   healthy   29   f    
HD-15   0   uninfected   healthy   36   f    
49   3   mild   mild   72   f   discharged  
56   3   mild   mild   58   f   discharged  
65   3   mild   mild   22   m   discharged  
66   3   mild   mild   75   f   discharged  
75   3   mild   mild   84   m   discharged  
38   4   mild   severe   70   m   discharged  
48   4   mild   severe   48   m   discharged  
50   4   mild   severe   78   m   discharged  
63   5   severe   severe   61   m   discharged  
57   6   severe   critical   55   f   discharged  
60   6   severe   critical   65   m   discharged  
62   6   severe   critical   72   m   discharged  
33   7   severe   critical   35   f   Still  hospitalized  
58   7   severe   critical   26   m   Still  hospitalized  
59   7   severe   critical   86   m   death  
61   7   severe   critical   54   m   Still  hospitalized  
64   7   severe   critical   57   m   Still  hospitalized  
 
*A  secondary  assessment  triggered  by  blind  proteome  clustering  (Figure  S3)  revealed  an                        
Influenza  Type  B  rather  than  a  COVID-19  infection.    
Table  S2.  WHO  scoring  for  COVID-19  cases  used  in  the  study  (World  Health  Organisation  
2020).  
Patient  state   Descriptor   Score  
Uninfected   No  clinical  or  virological  evidence  of  infection   0  
Ambulatory   No  limitation  of  activities   1  
Limitation  of  activities   2  
Hospitalised  -  mild  disease   No  oxygen  therapy   3  
Oxygen  by  mask  or  nasal  prongs   4  
Hospitalised  -  severe  disease   Non-invasive  ventilation  or  high-flow  oxygen   5  
Intubation  and  mechanical  ventilation   6  
Ventilation  +  additional  organ  support  (pressors,  
renal  replacement  therapy  (RRT),  extracorporeal  






Table  S3.  Proteins  differentially  expressed  depending  on  COVID-19  severity .   
 
Gene  symbols   Names   Possible  relevance  to  SARS-CoV-2  infection  
(speculative)  
Upregulated      
A1BG   Alpha-1B-Glycoprotein   Function  poorly  understood,  maybe  related  to  
hypoxia  as  indicated   from  a  study  in  cattle  (Kong  
et  al.,  2019) .  
ACTB;ACTG1   Actin  Beta  and  
Gamma-1  
F-actin  is  released  at  the  site  of  tissue  injury  and  
scavenged  by  plasma  Gelsolin  (DiNubile,  2008)  
C1R   Complement  C1r   Initiates  complement  activation  (Hajishengallis  et  
al.,  2017;  Ricklin  et  al.,  2010,  2016) .  
C1S   Complement  C1s   Initiates  complement  activation,  activated  by  C1R  
(Hajishengallis  et  al.,  2017;  Ricklin  et  al.,  2010,  
2016) .  
C8A   Complement  C8  Alpha  
Chain  
Part  of  the  complement  system  (Hajishengallis  et  
al.,  2017;  Ricklin  et  al.,  2010,  2016) .  
CD14   Monocyte  
Differentiation  Antigen  
CD14  
CD14  is  primarily  displayed  by  monocytes  and  
macrophages  and  can  be  released  in  a  soluble  
form;  soluble  CD14  is  also  produced  by  the  liver.  
Primarily  involved  in  the  recognition  of  bacterial  
LPS,  its  upregulation  might  be  indicative  in  
immune  response  dysregulation  by  SARS-CoV-2.  
CD14  has  also  been  implicated  in  a  broader  
spectrum  antigen  response  and  lung  inflammation  
(Anas  et  al.,  2010) .  Upregulation  of  CD14  
expression  levels  in  monocytes  was  previously  
reported  upon  SARS-Cov  infection  (Hu  et  al.,  
2012) .  Cytokines  can  induce  the  release  of  
soluble  CD14  (Shive  et  al.,  2015)  and  production  
of  soluble  CD14  in  the  liver  is  induced  by  IL-6  
(Bas  et  al.,  2004) .  
CFB   Complement  Factor  B   Part  of  the  alternative  complement  pathway  
(Hajishengallis  et  al.,  2017;  Ricklin  et  al.,  2010,  
2016) .  
 
CFH   Complement  Factor  H   Modulates  complement  activation  mainly  via  
inhibition  of  the  alternative  complement  pathway  
(Hajishengallis  et  al.,  2017;  Ricklin  et  al.,  2010,  
2016) .  
CFI   Complement  Factor  I   Modulates  complement  activity  via  degradation  of  
C3b  and  C4b  (Hajishengallis  et  al.,  2017;  Ricklin  
et  al.,  2010,  2016) .  
CRP   C-Reactive  Protein   Acute  phase  response  protein,  strongly  
upregulated  in  COVID-19  (Shi  et  al.,  2020) .  
FGA,  FGB,  FGG   Fibrinogen  Alpha,  Beta  
and  Gamma  Chains  
Fibrinogen  levels  are  elevated  in  acute-phase  
response  (Jain  et  al.,  2011) ,  upregulated  in  
COVID-19  (Shi  et  al.,  2020) .  
HP   Haptoglobin   Elevated  in  acute-phase  response  (Jain  et  al.,  
2011) .  Of  note,  HP  expression  is  known  to  be  
promoted  by  IL-6  (Li  et  al.,  2020) ,  which  is  
elevated  in  severe  COVID-19  (Ruan  et  al.,  2020) .  
ITIH3   Inter-Alpha-Trypsin  
Inhibitor  Heavy  Chain  3  
Involved  in  inflammatory  response  to  trauma  
(Hamm  et  al.,  2008)  
ITIH4   Inter-Alpha-Trypsin  
Inhibitor  Heavy  Chain  4  
Involved  in  inflammatory  response  to  trauma  
(Hamm  et  al.,  2008) .  Production  of  ITIH4  in  the  
liver  is  upregulated  by  IL-6  (Bhanumathy  et  al.,  
2002) .  
LBP   Lipopolysaccharide  
Binding  Protein  
Recognises  bacterial  LPS,  upregulation  might  be  
indicative  in  immune  response  dysregulation  by  
SARS-CoV-2.  
LGALS3BP   Galectin  3  Binding  
Protein  
Upregulated  in  viral  infections,  promotes  
inflammation  (Xu  et  al.,  2019) ,  has  been  shown  to  
induce  IL-6  expression  (Silverman  et  al.,  2012) .  
LRG1   Leucine-Rich  
Alpha-2-Glycoprotein  
LRG1  expression  is  induced  by  IL-6  (Shirai  et  al.,  
2009) ,  which  is  elevated  in  severe  COVID-19  
(Ruan  et  al.,  2020) .  LRG1  promotes  angiogenesis  
(Wang  et  al.,  2013)  and  has  been  reported  to  be  
associated  with  local  inflammation  (Naka  and  
Fujimoto,  2018) .  LRG1  is  known  to  promote  lung  
fibrosis  (Honda  et  al.,  2017) .  Secretion  of  LRG1  
by  neutrophils  upon  activation  has  been  reported  
(Druhan  et  al.,  2017) .  Of  note,  
neutrophil-lymphocyte-ratio  is  elevated  in  
COVID-19  (Qin  et  al.,  2020) .  
SAA1  and  
SAA1;SAA2  
Serum  Amyloid  A1  and  
A2  
SAA1  and  SAA2  are  markers  of  inflammatory  
response  and  tissue  injury  (Sack,  2018) .  
Expression  is  known  to  be  induced  by  IL-6  
(Hagihara  et  al.,  2004) .  
SERPINA10   Protein  Z-Dependent  
Protease  Inhibitor  
Acts  in  complex  with  Protein  Z  to  inhibit  the  F10a  
coagulation  factor  (Almawi  et  al.,  2013) ,  while  
coagulation  has  been  observed  to  be  increased  in  
severe  COVID-19  (Zhou  et  al.,  2020) .  
Downregulated      
ALB   Albumin   Low  levels  associated  with  acute-phase  response  
(Soeters  et  al.,  2019)  and  observed  in  critical  
COVID-19  (Zhou  et  al.,  2020) .  
APOA1   Apolipoprotein  A1   Major  component  of  the  High-Density  Lipoprotein  
(HDL)  complex,  which  is  a  modulator  of  innate  
immune  response  and  inflammation  (Fotakis  et  
al.,  2019;  Gordon  et  al.,  2011;  Macpherson  et  al.,  
2019;  White  et  al.,  2017) .  Although  it  might  be  
that  APOA1  levels  drop  upon  the  infection,  we  
can  also  speculate  that  low  APOA1  levels  are  a  
risk  factor  for  COVID-19.  Notably,  We  observe  
clear  correlation  of  APOA1  with  HDL  cholesterol  
and  only  weak  negative  correlation  with  age  
(Figure  S6).  Of  note,  decreased  APOA1  levels  
have  been  associated  with  poor  prognosis  in  
systemic  inflammatory  response  (Kumaraswamy  
et  al.,  2012;  Sirniö  et  al.,  2017;  Tani  et  al.,  2016) .  
APOC1   Apolipoprotein  C1   Part  of  multiple  apolipoprotein  complexes,  has  
links  to  immune  response  and  inflammation  (Fuior  
and  Gafencu,  2019) .  
GSN   Gelsolin   Low  levels  of  plasma  gelsolin  are  associated  with  
inflammation.  One  of  the  primary  mechanisms  
leading  to  this  is  believed  to  be  the  recruitment  of  
gelsolin,  which  has  actin  recycling  function,  to  the  
sites  of  tissue  injury,  depleting  its  plasma  levels.  
Of  note,  we  observed  increased  serum  levels  of  
the  ACTB;ACTG1  protein  group  in  severe  and  
critical  COVID-19  cases.  Importantly,  plasma  
gelsolin  is  a  modulator  of  inflammation,  which  
carries  a  protective  function  (DiNubile,  2008;  Li  et  
al.,  2012) .  Low  plasma  gelsolin  is  a  marker  of  
poor  prognosis  in  various  pathological  conditions,  
including  diabetes  (Khatri  et  al.,  2014) ,  cancers  
(Asare-Werehene  et  al.,  2019;  Stock  et  al.,  2015)  
and  sepsis  (Lee  et  al.,  2007) ,  leading  to  
suggestions  and  animal  tests  for  its  therapeutic  
use.  Of  note,  treatment  with  gelsolin  has  been  
observed  to  decrease  IL-6  levels  in  mice  (Cheng  
et  al.,  2017) .  Gelsolin  treatment  has  been  
suggested  to  promote  epithelial  repair  (Wittmann  
et  al.,  2018) .   
TF   Transferrin   Iron  carrier,  observed  to  decrease  in  acute  phase  




Table  S4. Date  of  symptom  onset  and  blood  sampling  for  the  patients  from  the                            
exploratory  cohort.   
 
Patient   Onset  of  
symptoms  
Admission  
to  hospital  
                                    blood  sampling  
1   15/02/2020   01/03/2020   02/03,04/03,06/03,07/03,09/03,10/03,11/03,12/03,13/03,16/03,1 
8/03,20/03,23/03,23/03,25/03,27/03  
2   25/02/2020   02/03/2020   04/03,06/03,07/03,08/03,09/03  
3   29/02/2020   11/03/2020   11/03,12/03,13/03,16/03,18/03,20/03,23/03,23/03,25/03  
5   28/02/2020   11/03/2020   12/03,13/03,16/03,18/03  
6   11/03/2020   12/03/2020   13/03,16/03,18/03  
7   08/03/2020   14/03/2020   16/03,19/03,20/03,23/03,25/03  
8   21/02/2020   15/03/20   20/03,23/03,25/03,27/03  
9   12/03/2020   16/03/2020   17/03,17/03,20/03,23/03,25/03,27/03  
10   09/03/2020   17/03/2020   19/03,20/03  
11   08/03/2020   17/03/2020   20/03,23/03,25/03,27/03  
12   21/02/2020   18/03/2020   17/03,20/03,23/03,25/03,27/03  
13   13/03/2020   19/03/2020   20/03,23/03,25/03,27/03  
14   15/03/2020   21/03/2020   23/03  
15   NA   17/03/2020   23/03,25/03  
16   19/03/2020   22/03/2020   23/03,25/03,27/03  
18   04/03/2020   10/30/2020   25/03  
19   14/03/2020   19/03/2020   23/03,25/03  
20   12/03/2020   20/30/2020   23/03,25/03,27/03  
21   12/03/2020   20/03/2020   23/03,25/03,27/03  
22   09/03/2020   18/03/2020   23/03,25/03,27/03  
23   NA   23/03/2020   23/03,25/03,27/03  
24   06/03/2020   21/03/2020   25/03,27/03  
25   NA   23/03/2020   25/03,27/03  
26   15/03/2020   24/03/2020   25/03,27/03  
27   12/03/2020   12/03/2020   25/03  
28   20/03/2020   23/03/2020   25/03  
29   13/03/2020   23/03/2020   25/03,27/03  
32   NA   21/03/2020   27/03  
34   21/03/2020   26/03/2020   27/03  
35   15/03/2020   25/03/2020   27/03  
37   10/03/2020   24/03/2020   27/03  
 
 
Table  S5. List  of  FDA  approved  biomarkers,  quantified  with  ultra-high-throughput  serum                      
proteomics.  
 
Protein  Name  
Albumin   





Antithrombin  III   






Complement  C1   
Complement  C1Q   
Complement  C3   
Complement  C4   
Complement  C5   
CRP  
Cystatin  C   
Factor  IX  antigen   
Factor  X   







Insulin-like  growth  factor  II   
IGFBP-3  
κ  light  chains   
λ  light  chains   
Lipoprotein  (a)   
Lysozyme   
Plasminogen   
Prealbumin  /  transthyretin  
Properdin  factor  B   
Protein  S   
Retinol  binding  protein   
Sex  hormone-binding  globulin   
Thyroxine  binding  globulin  
Transferrin  receptor   








Table  S6.  Lower  and  upper  m/z  limits  of  the  SWATH  precursor  selection  windows  used.  
 
Lower  m/z  limit   Upper  m/z  limit   CE  Spread  
449.5   468.9   5  
467.9   486.4   5  
485.4   503.3   5  
502.3   519.8   5  
518.8   535.7   5  
534.7   550.9   5  
549.9   565.5   5  
564.5   579.7   5  
578.7   594   5  
593   607.9   5  
606.9   621.9   5  
620.9   635.8   5  
634.8   649.7   5  
648.7   663.3   5  
662.3   676.3   5  
675.3   689.6   5  
688.6   702.9   5  
701.9   716.8   5  
715.8   732.3   5  
731.3   748.9   5  
747.9   766.4   5  
765.4   784.2   5  
783.2   803   5  
802   824.7   5  









Figure  S1,  Related  to  Figure  1.  Detailed  overview  of  the  high-throughput  proteomics  
workflow.  This  figure  details  the  documentation  and  management  tasks  orienting  on  ISO13485  





Figure  S2. Quality  parameters  of  protein  quantification  in  ultra-high-throughput                  
proteomics.  a .  Coefficient  of  Variation  (%)  as  a  function  of  log2  mean  protein  intensity  for  39                                
repeated  injections  of  a  pooled  whole-serum  tryptic  digest  that  were  run  over  a  period  of  >  4                                  
days,  to  test  for  instrument  stability..  b.  Median  CV  value  for  low,  middle,  and  high-intensity                              
proteins  in  the  39  repeated  injections. c.  Number  of  precursors  identified  in  5-min  high-flow                            
SWATH  runs  with  different  amounts  of  serum  proteins  injected. d.  Number  of  precursors                          
identified  in  a  plasma  sample  with  different  amounts  of  trypsin  used  for  digestion,  run  with  a                                
20-min  water  to  acetonitrile  gradient. e.  Proteins  identified  in  triplicate  injections  of  a  mammalian                            
(K562)  cell  lysate  using  the  5-minute  high-flow  SWATH  runs  presented  in  this  study.  Total                            
number  of  unique  Proteins  (1%  FDR),  number  of  unique  Proteins  quantified  with  less  than  20%                              















Figure  S3:  Clustering  of  untargeted  plasma  proteomes  led  to  the  reclassification  of  two  
study  participants.  Principal  component  analysis  based  on  proteins  differentially  expressed  
depending  on  COVID-19  severity  grading  according  to  WHO.  Patients  4  and  6  were  initially  
clinically  assessed  as  “severe”  (Braun  et  al,  2020)  but  clustered  with  patients  that  suffered  from  
a  mild  form  of  COVID-19.  A  retrospective  assessment  revealed  that  patient  6  had  received  
R-CHOP  chemotherapy  10  days  prior  to  study  inclusion  and  patient  4  was  in  fact  suffering  from  
type  B  influenza  rather  than  SARS-CoV-2  infection.  Patient  6  was  categorized  as  mild  by  using  
the  WHO  ordinal  outcome  scale  of  clinical  improvement  (World  Health  Organisation,  2020)  and  
Patient  4  was  removed  from  the  analysis.  Please  note  that  the  PCA  transformation  is  slightly  
different  from  that  in  Figure  4b,  as  the  addition  of  two  extra  samples  for  patient  4  led  to  slightly  
different  protein  quantities  being  calculated  for  all  the  samples  by  the  MaxLFQ  algorithm  (Cox  et  










Figure  S4. Proteomes  in  mild,  severe  and  critical  SARS-CoV-2  infection  for  patients  in  the                            
validation  cohort .  Differentially  expressed  proteins  are  highlighted  with  colours  depending  on                      








Figure  S5. Differential  response  of  peptide  precursors  mapping  to  PF4  and  PPBP .                        
Boxplots  are  presented  for  log 2 -transformed  peptide  precursor  quantities.  The  peptide  precursor                      
charge  is  indicated  with  a  number  after  the  amino  acid  sequence.  All  cysteines  were  considered                              
carbamidomethylated.  Boxplots  are  drawn  based  on  individual  measurements  (multiple                  
timepoints  per  patient),  which  are  indicated  with  points  (different  colours  for  different  patients,                          
ordered  from  left  to  right  by  the  time  taken).  Standard  Serum  sample  preparation  controls  are                              
indicated  with  “SS”  and  represent  the  technical  variability  (sample  preparation  +  LC-MS).  The                          
last  box  represents  the  variability  seen  in  the  GS  study;  as  the  absolute  quantities  from  the  two                                  
studies  cannot  be  compared  directly  (the  data  was  acquired  on  different  LC-MS  setups),  to                            
simplify  the  visual  assessment  of  the  variability,  the  median  of  GS  quantities  was  matched  to  the                                










Figure  S6. Log 2 -transformed  serum  levels  of  Apolipoprotein  A1  (APOA1;  arbitrary  units)                      















Figure  S7  (following  18  pages). Proteomes  in  mild,  severe  and  critical  SARS-CoV-2                        
infection  (complete  list) .  Differentially  expressed  proteins  are  highlighted  with  colours                    
depending  on  the  multiple  testing-corrected  p-values:  green:  P  <  0.05,  yellow:  P  <  0.01,  orange:                              









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.0 C1QB, P=0.33, FC=1.7
































































































































































































































































































































































































































































.0 C1S, P=0.002, FC=2.4





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.0 C9, P=1, FC=1.4














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0 CFHR1;CFHR2, P=NA, FC=1.8



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5 F11, P=NA, FC=2.8
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.0 IGHG2, P=0.78, FC=0.68
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.5 IGKV1−5, P=NA, FC=0.74
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APOA1 APOA2 APOA4 APOB
ALB AMBP ANXA1 APCS
ADIPOQ AFM AGT AHSG
A1BG A2M A2M;PZP A1;ACTA2;ACTB;ACTC1;ACTG1;ACTG2
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
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BCHE BTD C18orf63 C1QA
APOL1 APOM ATRN AZGP1
APOD APOE APOF APOH
APOC1 APOC2 APOC3 APOC4
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C4A;C4B C4B C4BPA C4BPB
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CFHR1 CFHR1;CFHR2 CFHR1;CFHR5 CFHR2
CFD CFH CFH;CFHR1 CFH;CFHR1;CFHR2
CD14 CD44 CD5L CFB
C8B C8G C9 CARD9
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F11;KLKB1 F12 F13B F2
CPN2 ECM1 F10 F11
CNDP1 CP CPB2 CPN1
CFI CFP CLEC3B CLU
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IGHV2−26 IGHV2−5 IGHV3−13 IGHV3−13;IGHV3−20;IGHV3−21;IGHV3−43;IGHV3−7
IGHV1−3;IGHV1−46;IGHV1−69;IGHV1−69D IGHV1−45 IGHV1−46 IGHV1−69
IGHG2;IGHG4 IGHG3 IGHG4 IGHM
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IGHV4−28 IGHV4−38−2 IGHV5−10−1;IGHV5−51 IGHV5−51
IGHV3−49;IGHV3−73 IGHV3−64D IGHV3−7 IGHV3−72
IGHV3−23;IGHV3−53;IGHV3−74 IGHV3−30;IGHV3−30−5 IGHV3−43D IGHV3−49
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IGKV3−11 IGKV3−15 IGKV3−15;IGKV3D−7 IGKV3−20
IGKV1−5 IGKV1D−16 IGKV2−24 IGKV2−30
IGKV1−16 IGKV1−17 IGKV1−27;IGKV1−8 IGKV1−33;IGKV1D−33
IGHV6−1 IGKC IGKV1−12;IGKV1−39;IGKV1D−12;IGKV1D−39 IGKV1−13;IGKV1D−13
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IGLV2−8 IGLV3−10 IGLV3−10;IGLV3−25 IGLV3−12;IGLV3−21;IGLV3−9
IGLV1−40 IGLV1−44;IGLV1−47 IGLV1−51 IGLV2−11
IGLC7 IGLC7;IGLL5 IGLL1 IGLL5
IGKV3−20;IGKV3D−20 IGKV3D−20 IGKV4−1 IGLC2;IGLC3
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80












































































KNG1 LBP LCAT LGALS3BP
ITIH3 ITIH4 JCHAIN KLKB1
IGLV4−69 IGLV8−61 ITIH1 ITIH2
IGLV3−16;IGLV3−25;IGLV3−27 IGLV3−19 IGLV3−21;IGLV3−9 IGLV3−9
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80









































































PON1 PON3 PPBP PRG4
PGLYRP2 PLG PNPLA8 POLQ
MASP1 ORM1 ORM1;ORM2 ORM2
LPA LPA;PLG LRG1 LUM
40 50 60 70 80 40 50 60 70 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80


































































SERPINC1 SERPIND1 SERPINF1 SERPINF2
SERPINA3 SERPINA4 SERPINA6 SERPINA7
SELENOP SELL SERPINA1 SERPINA10
PROS1 PZP RBP4 SAA4
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80




































































TTR VTN VWF ZGRF1
SERPING1 SHBG TF TGFBI
40 50 60 70 80 40 50 60 70 80 40 50 60 70 80 40 50 60 70 80
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